Women with Alzheimer’s live longer than men with the disease, and scientists at UC San Francisco now have evidence from research in both humans and mice that this is because they have genetic protection from the ravages of the disease.
By virtue of having a second X chromosome, women get two “doses” of a protective protein from a gene that only exists on this female sex chromosome. Some people, both male and female, have an especially potent variant of this gene, which is called KDM6A, that gives them even more protection. But, because of the way sex chromosomes work – women have two X’s, but men only have one – women have two copies of this gene churning out the protective protein.
The new study offers a first look at how sex chromosomes affect vulnerability to Alzheimer’s. And it helps explain why women survive longer and with less severe symptoms than men during early stages of the disease, even when they have comparable levels of toxic Alzheimer’s proteins in their brains.
“This finding challenges a long-standing dogma that women are more vulnerable to Alzheimer’s,” said Dena Dubal, MD, PhD, associate professor of neurology at UCSF and senior author of the study, published Aug. 26, 2020, in Science Translational Medicine. Dubal is the David Coulter Endowed Chair in Aging and Neurodegenerative Disease, and a member of the UCSF Weill Institute for Neurosciences. “More women than men have Alzheimer’s because they survive to older ages, when risk is highest. But they also survive with the disease for longer.”
Zeroing In On One Active Gene
While much of a female’s second X chromosome is “silenced” by an outer layer of non-coding RNA, a small number of genes escape this process, in both mice and humans, giving females twice the dose of the proteins coded for by those genes. The researchers zeroed in on one of these active genes, KDM6A, which is already known to be involved in learning and cognition. When this gene malfunctions, it causes Kabuki syndrome, which is characterized by developmental delay and mild to severe intellectual disability.
Combing through public databases of gene expression studies, the scientists discovered an especially active variant of KDM6A that is carried by about 13 percent of women and 7 percent of men around the world. Because women have two X chromosomes, they have a greater chance of carrying at least one copy of this variant, and some women carry two copies.
When the scientists looked at several long-term studies of older people, many of whom already had mild cognitive impairment, they could see that women with one copy – or even better, two copies – of the variant appeared to progress more slowly toward Alzheimer’s. It’s not yet clear if the same holds true for men who carry the variant on their X chromosome, since there may have been too few of them in the study to see any effects.
Little is known about the ways that genetics drive differences in how diseases affect men and women, said Jennifer Yokoyama, PhD, an associate professor of neurology at the UCSF Memory and Aging Center and member of the Weill Institute, who analyzed the KDM6A variant in the new study. “Because the X and Y chromosomes are hard to compare to one another, the big genome-wide association studies have all been done on non-sex chromosomes,” Yokoyama said. “Perhaps our study will highlight the fact that there could be something pretty interesting on the X chromosome after all.”
The gene expression studies showed that women in general had more KDM6A protein in their brains than men. They also showed that people with Alzheimer’s had more of the protein in brain regions that get damaged early in the disease. The researchers theorized that neurons in these regions may produce more of the protein to protect against the disease, although the data they analyzed could only identify associations, and not prove causes.
Showing Benefit of Second X Chromosome
To get closer to this causal question, the scientists performed experiments in mice. First, they looked inside the brains of female mice and confirmed that both copies of Kdm6a were actively transcribing RNA to make protein. Female mice had significantly higher levels of this protein in a brain region called the hippocampus, which is critical to learning and memory and gets damaged early in Alzheimer’s.
Then they bred mice which model human Alzheimer’s by producing toxic amyloid beta in their brains, so their male offspring produced amyloid and also carried two X chromosomes like females.
With a second X chromosome, the male mice did better on cognitive tests, and they also lived longer, despite the toxic proteins in their brains. To be sure it was the second X that provided protection, rather than the absence of a Y chromosome, scientists deleted the second X from female Alzheimer’s mice. And just like males, these female mice were more cognitively impaired and died faster.
In further tests, when the scientists exposed neurons from male and female mouse brains to increasing doses of amyloid beta, the male neurons died faster. But this difference was eliminated when the scientists used a gene editing technique to reduce Kdm6a protein levels in the neurons from females’ brains and increased it in the neurons from male mouse brains.
The researchers built on these findings by increasing Kdm6a in a region of the hippocampus called the dentate gyrus, which is involved in spatial learning and memory, in male Alzheimer’s mice. One month later, the male mice had as much of the gene’s protein in that brain region as the female mice. These males also did significantly better on tests of spatial memory than male mice without the added Kdm6a.
“Our study reveals a new role for sex chromosomes,” Dubal said. “This protective mechanism on the X chromosome opens the possibility that we could increase resilience to Alzheimer’s and other neurodegenerative disorders by boosting KDM6A or other X factors in both men and women.”
Authors: Emily J. Davis, Lauren Broestl, Samira Abdulai-Saiku, Kurtresha Worden, Luke W. Bonham, Elena Miñones-Moyano, Arturo J. Moreno, Dan Wang, Kevin Chang, Gina Williams, Bayardo I. Garay, Iryna Lobach, Bruce L. Miller, Jorge J. Palop, Barbara Panning, Jennifer S. Yokoyama, and Dena B. Dubal, of UCSF; Cliff Anderson-Bergman, Nino Devidze, Daniel Kim, Gui-Qiu Yu, and Lennart Mucke, of the Gladstone Institutes; Charles White and David A. Bennett, of Rush University Medical Center; Phil L. De Jager, of Columbia University Medical Center; Julie A. Harris, of the Allen Institute for Brain Science; and Arthur P. Arnold, of UCLA.
Funding: Primary support for mouse studies and human analyses was provided by NSF grant 1650113 (E.J.D.), NIH grants NS092918 and AG034531 (D.B.D.), AG049152 (J.S.Y.), and CTSI UL1 TR000004 (I.L.); the Larry L. Hillblom Foundation (L.W.B. and J.S.Y.), the Coulter-Weeks Foundation, (D.B.D), the Bakar Family Foundation (D.B.D), American Federation for Aging Research (E.J.D, D.B.D), and the Glenn Foundation for Medical Research (D.B.D). Additional support was provided by NIH grants AG023501 (B.L.M.), NS043196 (A.P.A.), AG011385 and NS065780 (L.M.), P30AG10161, R01AG15819, and R01AG17917 (D.A.B.), U01AG46152 and U01AG61356 (P.L.D and D.A.B.), and R01AG36836 (P.L.D).
Disclosures: D.A.B. has consulted for AbbVie, Inc., Data Monitoring Committee, ABBV-8E12 Study and serves on the Scientific Advisory Board for Vigorous Minds Inc.; L.M. has consulted for Abingworth, Eisai, Sangamo Therapeutics and serves on the Scientific Advisory Board for Alkahest, Arvinas Operations, Biogen, and Dolby Family Ventures; D.B.D. has consulted for Unity Biotechnology.
